Baird Medical to Participate in NASIT 2025 Conference
Baird Medical Investment Holdings (NASDAQ: BDMD) has announced its participation in the 2025 North American Society for Interventional Thyroidology (NASIT) Conference, scheduled for January 31 – February 1, 2025, in Washington, D.C. The company, known for its leadership in Minimally Invasive Microwave Ablation (MWA) technology, will return to this premier thyroid interventions forum.
During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, following his achievement of completing 100 MWA cases. The event provides Baird Medical with opportunities to engage with global experts, industry leaders, and potential partners while contributing to discussions on MWA technology advancements.
The company aims to gain insights into industry trends, optimize strategic initiatives, and continue driving innovation in global healthcare through this participation.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha annunciato la sua partecipazione alla Conferenza 2025 della North American Society for Interventional Thyroidology (NASIT), programmata per il 31 gennaio – 1 febbraio 2025, a Washington, D.C. L'azienda, nota per il suo ruolo di leadership nella tecnologia di Ablazione Microonde Minimante Invasiva (MWA), ritorna a questo prestigioso forum sulle interventi alla tiroide.
Durante la conferenza, Dr. Emad Kandil, Professore e Presidente Ellis Hanna in Chirurgia presso la Tulane University School of Medicine, presenterà al Product Theater, dopo aver raggiunto il traguardo di 100 casi di MWA. L'evento offre a Baird Medical l'opportunità di interagire con esperti globali, leader del settore e potenziali partner, contribuendo allo scambio di opinioni sui progressi della tecnologia MWA.
L'azienda punta a ottenere intuizioni sulle tendenze di settore, ottimizzare iniziative strategiche e continuare a promuovere l'innovazione nella sanità globale attraverso questa partecipazione.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha anunciado su participación en la Conferencia 2025 de la North American Society for Interventional Thyroidology (NASIT), programada para el 31 de enero - 1 de febrero de 2025, en Washington, D.C. La compañía, reconocida por su liderazgo en la tecnología de Ablación por Microondas Mínimamente Invasiva (MWA), regresará a este importante foro de intervenciones tiroideas.
Durante la conferencia, Dr. Emad Kandil, Profesor y Presidente Ellis Hanna en Cirugía en la Tulane University School of Medicine, presentará en el Product Theater, tras alcanzar su logro de completar 100 casos de MWA. El evento brinda a Baird Medical la oportunidad de interactuar con expertos globales, líderes de la industria y posibles socios, al tiempo que contribuye a las discusiones sobre los avances en la tecnología MWA.
La empresa busca obtener información sobre las tendencias del sector, optimizar iniciativas estratégicas y continuar impulsando la innovación en la atención médica global a través de esta participación.
Baird Medical Investment Holdings (NASDAQ: BDMD)는 2025년 1월 31일부터 2월 1일까지 워싱턴 D.C.에서 열리는 2025 북미 개입 갑상선학회(NASIT) 컨퍼런스에 참가한다고 발표했습니다. 최소 침습 마이크로웨이브 절제(MWA) 기술 분야에서 선두주자인 이 회사는 이번 갑상선 개입 포럼에 다시 참가합니다.
컨퍼런스 중에 Emad Kandil 박사가 튤레인 대학교 의과대학의 외과학 교수이자 엘리스를 한나 의장으로서 Product Theater에서 100개의 MWA 사례를 완료한 성과를 발표할 예정입니다. 이 행사는 Baird Medical에게 글로벌 전문가, 산업 리더 및 잠재 파트너와 소통할 수 있는 기회를 제공하며, MWA 기술 발전에 대한 논의에 기여합니다.
회사는 이 참여를 통해 산업 동향에 대한 통찰력을 얻고, 전략적 이니셔티브를 최적화하며, 글로벌 의료 분야에서 혁신을 지속적으로 추진하는 것을 목표로 하고 있습니다.
Baird Medical Investment Holdings (NASDAQ: BDMD) a annoncé sa participation à la Conférence 2025 de la North American Society for Interventional Thyroidology (NASIT), prévue du 31 janvier au 1er février 2025 à Washington, D.C. L'entreprise, reconnue pour son leadership dans la technologie d'Ablation par Micro-ondes Minimement Invasive (MWA), fera son retour à ce forum de premier plan pour les interventions sur la thyroïde.
Durant la conférence, Dr. Emad Kandil, Professeur et Président Ellis Hanna en Chirurgie à l'École de Médecine de l'Université de Tulane, présentera au Product Theater, après avoir atteint son exploit de 100 cas de MWA. Cet événement offre à Baird Medical des opportunités d'échanger avec des experts mondiaux, des leaders de l'industrie et des partenaires potentiels tout en contribuant aux discussions sur les avancées technologiques en MWA.
L'entreprise vise à obtenir des perspectives sur les tendances du secteur, optimiser les initiatives stratégiques et continuer à promouvoir l'innovation dans la santé mondiale grâce à cette participation.
Baird Medical Investment Holdings (NASDAQ: BDMD) hat seine Teilnahme an der 2025 North American Society for Interventional Thyroidology (NASIT) Konferenz angekündigt, die vom 31. Januar bis 1. Februar 2025 in Washington, D.C. stattfinden wird. Das Unternehmen, bekannt für seine Führungsposition in der minimal-invasiven Mikrowellen-Ablation (MWA) Technologie, wird zu diesem herausragenden Forum für Schilddrüseninterventionen zurückkehren.
Während der Konferenz wird Dr. Emad Kandil, Professor und Ellis Hanna Chair für Chirurgie an der Tulane University School of Medicine, im Product Theater präsentieren, nachdem er 100 MWA-Fälle abgeschlossen hat. Die Veranstaltung bietet Baird Medical die Möglichkeit, mit globalen Experten, Branchenführern und potenziellen Partnern in Kontakt zu treten und an Diskussionen über Fortschritte in der MWA-Technologie teilzunehmen.
Das Unternehmen hat das Ziel, Einblicke in Branchenentwicklungen zu gewinnen, strategische Initiativen zu optimieren und die Innovation im globalen Gesundheitswesen durch diese Teilnahme weiter voranzutreiben.
- None.
- None.
The NASIT Conference is a premier forum for education, research, and collaboration in thyroid interventions, and Baird Medical is honored to participate in this key industry event. The Company's invitation highlights its growing prominence in the field of microwave ablation while offering a valuable opportunity to engage with global experts, industry leaders, and potential partners.
As a returning participant, Baird Medical is excited to contribute to discussions on the latest advancements in MWA technology and to collaborate with leading experts in interventional thyroidology. The Company also sees this as an opportunity to gain deeper insights into industry trends, optimize its strategic initiatives, and continue driving innovation and growth in global healthcare.
During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, building on his recent milestone of completing 100 MWA cases. His session will provide insights into clinical experiences with MWA in thyroid care.
Baird Medical remains committed to supporting the ongoing advancement of minimally invasive technologies and collaborating with healthcare professionals to explore innovative approaches in thyroid treatment.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
About NASIT
The North American Society for Interventional Thyroidology (NASIT) is the largest multidisciplinary group in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-nasit-2025-conference-302359444.html
SOURCE BDMD
FAQ
When and where is Baird Medical (BDMD) participating in the NASIT 2025 Conference?
What will Dr. Kandil present at the NASIT 2025 Conference regarding BDMD's technology?
What is the significance of BDMD's participation in the NASIT 2025 Conference?
How many MWA cases has Dr. Kandil completed before the NASIT 2025 Conference?
What technology is BDMD showcasing at the NASIT 2025 Conference?
